MYO Quote, Financials, Valuation and Earnings

Electromed has a net margin of -2.16% compared to Myomo's net margin of 12.11%. Myomo's return on equity of -48.64% beat Electromed's return on equity of 15.91%.

Myomo has a consensus price target of $9.25, signalling upside risk potential of 112.64%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 65.25%. Given that Myomo has higher upside potential than Electromed, analysts believe Myomo is more attractive than Electromed.

Myomo has a beta of 1.548, which suggesting that the stock is 54.752% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are smaller than Electromed quarterly revenues of $16.3M. Myomo's net income of -$260.1K is lower than Electromed's net income of $2M. Notably, Myomo's price-to-earnings ratio is -- while Electromed's PE ratio is 29.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 5.05x versus 3.36x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Nevro has a net margin of -2.16% compared to Myomo's net margin of -50.32%. Myomo's return on equity of -48.64% beat Nevro's return on equity of -42%.

Myomo has a consensus price target of $9.25, signalling upside risk potential of 112.64%. On the other hand Nevro has an analysts' consensus of $7.68 which suggests that it could grow by 31.42%. Given that Myomo has higher upside potential than Nevro, analysts believe Myomo is more attractive than Nevro.

Myomo has a beta of 1.548, which suggesting that the stock is 54.752% more volatile than S&P 500. In comparison Nevro has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.343%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nevro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. Nevro pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are smaller than Nevro quarterly revenues of $105.5M. Myomo's net income of -$260.1K is higher than Nevro's net income of -$53.1M. Notably, Myomo's price-to-earnings ratio is -- while Nevro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 5.05x versus 0.53x for Nevro. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -2.16% compared to Myomo's net margin of -118.53%. Myomo's return on equity of -48.64% beat Stereotaxis's return on equity of -139.2%.

Myomo has a consensus price target of $9.25, signalling upside risk potential of 112.64%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 171.08%. Given that Stereotaxis has higher upside potential than Myomo, analysts believe Stereotaxis is more attractive than Myomo.

Myomo has a beta of 1.548, which suggesting that the stock is 54.752% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are larger than Stereotaxis quarterly revenues of $6.3M. Myomo's net income of -$260.1K is higher than Stereotaxis's net income of -$7.5M. Notably, Myomo's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 5.05x versus 5.25x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

Viemed Healthcare has a net margin of -2.16% compared to Myomo's net margin of 7.11%. Myomo's return on equity of -48.64% beat Viemed Healthcare's return on equity of 9.21%.

Myomo has a consensus price target of $9.25, signalling upside risk potential of 112.64%. On the other hand Viemed Healthcare has an analysts' consensus of $12.83 which suggests that it could grow by 86.53%. Given that Myomo has higher upside potential than Viemed Healthcare, analysts believe Myomo is more attractive than Viemed Healthcare.

Myomo has a beta of 1.548, which suggesting that the stock is 54.752% more volatile than S&P 500. In comparison Viemed Healthcare has a beta of 1.636, suggesting its more volatile than the S&P 500 by 63.604%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. Viemed Healthcare pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are smaller than Viemed Healthcare quarterly revenues of $60.7M. Myomo's net income of -$260.1K is lower than Viemed Healthcare's net income of $4.3M. Notably, Myomo's price-to-earnings ratio is -- while Viemed Healthcare's PE ratio is 24.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 5.05x versus 1.25x for Viemed Healthcare. Usually stocks with elevated PS ratios are considered overvalued.